Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,892 active trials21 approved drugs383 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03828227 | QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.(COLAGE) | active not recruiting | Phase 3 | 49 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06199973 | Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan | active not recruiting | Phase 3 | 130 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| 1 |
| Jul 17, 2025 |
| clinicaltrials |
| NCT07070622 | Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)(OPLAR) | recruiting | Phase 3 | 186 | West China HospitalOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04922853 | Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer(COPEC) | active not recruiting | Phase 3 | 554 | West China HospitalOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT02885753 | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver(OSCAR) | recruiting | Phase 3 | 348 | Federation Francophone de Cancerologie DigestiveOTHER | 2 | Jul 9, 2025 | clinicaltrials |
| NCT07025239 | QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer | not yet recruiting | Phase 3 | 430 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 17, 2025 | clinicaltrials |
| NCT07020247 | Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study | recruiting | Phase 3 | 184 | West China HospitalOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | active not recruiting | Phase 3 | 11,000 | University College, LondonOTHER | 2 | Jun 10, 2025 | clinicaltrials |
| NCT04861558 | Efficacy of Hyperthermic Intraperitoneal Chemotherapy(EFFIPEC) | recruiting | Phase 3 | 213 | Uppsala UniversityOTHER | 2 | May 30, 2025 | clinicaltrials |
| NCT06208371 | Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM | recruiting | Phase 3 | 117 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT05141721 | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 700 | Seattle Project CorporationINDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT06968221 | Bovine Reinforcement in Stomach, Colorectal and Lung Operation | recruiting | Phase 3 | 172 | Shanghai Cingularbio Co. LtdINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT04068103 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | active not recruiting | Phase 2 / Phase 3 | 635 | NRG OncologyOTHER | 3 | May 7, 2025 | clinicaltrials |
| NCT06959693 | A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC) | not yet recruiting | Phase 2 / Phase 3 | 590 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT03428477 | EPA for Metastasis Trial 2(EMT2) | active not recruiting | Phase 3 | 418 | Mark A Hull, PhD FRCPOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05646511 | TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer(ENSEMBLE) | recruiting | Phase 3 | 608 | National Cancer Center Hospital EastOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06293625 | Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More(FOxTROT2France) | recruiting | Phase 3 | 150 | Centre Hospitalier Universitaire DijonOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06899477 | Pre-Operative Treatment in REseCTable COlon CanceR | not yet recruiting | Phase 3 | 714 | Dominik Paul ModestOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06857773 | Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy(PUMP-IT RCT) | recruiting | Phase 3 | 306 | The Netherlands Cancer InstituteOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05709249 | Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer | recruiting | Phase 3 | 730 | Jiangsu Famous Medical Technology Co., Ltd.INDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT02843191 | Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy | active not recruiting | Phase 3 | 358 | Kyung Hee University Hospital at GangdongOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05462613 | Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer(REPROGRAM-02) | recruiting | Phase 2 / Phase 3 | 446 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04687631 | Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases | recruiting | Phase 3 | 508 | Fudan UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06709144 | Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer(BLARCC) | active not recruiting | Phase 3 | 896 | Haixing Ju, MDOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06520683 | Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer(SMALLER) | recruiting | Phase 3 | 180 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04516681 | Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer | recruiting | Phase 3 | 400 | Fudan UniversityOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03635021 | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer(CR-SEQUENCE) | active not recruiting | Phase 3 | 419 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT04547166 | A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 2 / Phase 3 | 568 | Shanghai Henlius BiotechINDUSTRY | 2 | Oct 17, 2024 | clinicaltrials |
| NCT06275958 | DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer(DOSAGE) | recruiting | Phase 3 | 587 | Leiden University Medical CenterOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06616259 | First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study(CAPCET-III) | not yet recruiting | Phase 3 | 452 | Meng QiuOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06609551 | ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study(ZJCH-CRCC-1) | recruiting | Phase 3 | 312 | Zhejiang Cancer HospitalOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT05168839 | Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage(FLUOCOL-1) | recruiting | Phase 3 | 1,010 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06185556 | COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases(COLDFIRE-III) | recruiting | Phase 2 / Phase 3 | 78 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06566755 | Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer | recruiting | Phase 3 | 30 | Caigang LiuOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05939687 | Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection(ProMeLAR) | recruiting | Phase 3 | 142 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06509126 | Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer(IMPROVE-2) | recruiting | Phase 3 | 500 | National Cancer Institute, NaplesOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06243393 | Sacituzumab Govitecan in Metastatic Colorectal Cancer(TROPHIT1) | recruiting | Phase 2 / Phase 3 | 80 | University Hospital HeidelbergOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06450574 | Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)(TAUTEM-T1) | not yet recruiting | Phase 3 | 106 | Corporacion Parc TauliOTHER | 0 | Jun 10, 2024 | clinicaltrials |
| NCT06443671 | Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer(PKUCH-R09) | not yet recruiting | Phase 2 / Phase 3 | 132 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT05954078 | Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer | recruiting | Phase 3 | 340 | Fudan UniversityOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT03659448 | Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer | recruiting | Phase 3 | 300 | SurgimabINDUSTRY | 4 | Apr 24, 2024 | clinicaltrials |
| NCT06343116 | Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer(NOTABLE-308) | not yet recruiting | Phase 3 | 420 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Apr 2, 2024 | clinicaltrials |
| NCT03464305 | ASPIRIN Trial Belgium(ASPIRIN) | active not recruiting | Phase 3 | 148 | University Hospital, AntwerpOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT02301286 | A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients(ASPIRIN) | active not recruiting | Phase 3 | 770 | Leiden UniversityOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03413254 | Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases(COLOPEC-II) | active not recruiting | Phase 3 | 389 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06226857 | Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer(CRC01) | recruiting | Phase 3 | 355 | City Clinical Oncology Hospital No 1OTHER_GOV | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06229041 | Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) | recruiting | Phase 3 | 472 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06134388 | Sulfasalazine in Patients With Metastatic Colorectal Cancer | recruiting | Phase 3 | 50 | Tanta UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 18, 2025source: clinicaltrials